Login
Navigate Fool.com
Will VVUS beat
the market?

VIVUS, Inc.

NASDAQ: VVUS

Community Rating: 2 Stars: Unattractive

5.12 -0.18 (-3.40%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.30
Previous Close $5.30
Daily Range $5.11 - $5.30
52-Week Range $4.71 - $15.62
Market Cap $528.9M
P/E Ratio -3.08
Dividend (Yield) $0.00 (0.0%)
Volume 1,543,724
Average Daily Volume 3,125,280
Current FY EPS -$1.65

How do you think VVUS
will perform against the market?

Top VVUS Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted June 15, 2010

I had Vivus on my watchlist to green thumb under 11 ahead of the FDA advisory panel for Qnexa on July 15, and surely enough they dropped a clean point today and slipped under my threshold. Some jitter … More

5 Replies Reply Report this Post
 

JPG101 (< 20)
Submitted July 20, 2010

I'm back at giving them a thumbs down (seems more efficient from a CAPS perspective to 'short' a stock more then once as they are going down). From and earlier post where I gave a thumbs down to th … More

0 Replies Reply Report this Post

News & Commentary

Biotech Earnings Preview

A rundown of what to expect from Gilead Sciences, Arena Pharmaceuticals, and Biogen Idec.

1 of These 3 Cratering Biotechs is a Buy

Biotech stocks have been performing poorly in general this year. However, some biotechs have been having a truly terrible year. Here's a look at the three worst-performing biotechs and their respective chances at making a comeback.

Biotech Tweet of the Week: Love Being Private

Investors often ignore private biotechs because they can't buy shares, but investors in companies such as InterMune and the obesity drug makers -- Arena Pharmaceuticals, VIVUS, and Orexigen -- need to follow their privately-held competitors.

Who Benefits the Most With Obamacare's Enrollment Surpassing 7 Million?

Some expected and surprising beneficiaries could emerge from Obamacare's stronger-than-expected enrollment figures.

Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

Stock Downgrades: It's Open Season on Citigroup

Wall Street ratings agencies set the tone for today's stock market.

Stock Downgrades: Citigroup, Broadcom, and Vivus

Wall Street ratings agencies set the tone for today's stock market.

Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.

Today's top stories in health care and biotech.

Sector Update: Healthcare Shares Mixed Pre-Market; Vivus Sinks 5% on Piper Jaffray Downgrade

MannKind's Dominating Win Annihilates the Shorts

One of the biggest winners on the entire market today sends the short sellers packing.

See More VVUS News...

Sector

Healthcare

Industry

Drugs

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website: http://www.vivus.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks